The purpose of this study was to validate an integrin a v b 3 -targeted magnetic resonance contrast agent, PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 , for its ability to detect tumor angiogenesis and assess early response to antiangiogenic therapy using dynamic contrastenhanced (DCE) magnetic resonance imaging (MRI). Integrin a v b 3 -positive U87 cells and control groups were incubated with fluorescein-labeled cRGD-conjugated dendrimer, and the cellular attachment of the dendrimer was observed. DCE MRI was performed on mice bearing KB xenograft tumors using either PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 or PEG-G3-(Gd-DTPA) 6 -(cRAD-DTPA) 2 . DCE MRI was also performed 2 hours after anti-integrin a v b 3 monoclonal antibody treatment and after bevacizumab treatment on days 3 and 6t. Using DCE MRI, the 30-minute contrast washout percentage was significantly lower in the cRGDconjugate injection groups. The enhancement patterns were different between the two contrast injection groups. In the antiangiogenic therapy groups, a rapid increase in 30-minute contrast washout percentage was observed in both the LM609 and bevacizumab treatment groups, and this occurred before there was an observable decrease in tumor size. The integrin a v b 3 targeting ability of PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 in vitro and in vivo was demonstrated. The 30-minute contrast washout percentage is a useful parameter for examining tumor angiogenesis and for the early assessment of antiangiogenic treatment response.
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F
OR THE GROWTH AND METASTASIS of solid tumors, angiogenesis is a necessary process. 1, 2 Focusing on angiogenetic factors, antiangiogenic therapy in conjunction with chemotherapy has already proved to be an effective treatment for non-small cell lung cancer, metastatic colon cancer, and metastatic breast cancer. [3] [4] [5] However, because these therapies are expensive and have potential adverse effects, a need exists to screen for tumor angiogenesis before initiating antiangiogenic therapy. A noninvasive imaging method would be invaluable if it could detect the presence of tumor angiogenesis, and, furthermore, help identify an individual who will respond to future antiangiogenic therapy. Integrin a v b 3 is highly expressed on proliferating vascular endothelial cells and is considered to be a biomarker of tumor-induced angiogenesis; its expression level correlates well with tumor invasiveness and disease state, whereas it is essentially absent on mature quiescent cells. [6] [7] [8] [9] The introduction of anti-integrin a v b 3 monoclonal antibody (MAb) is able to promote tumor regression by inducing apoptosis of angiogenic blood vessels. 10, 11 Owing to its restricted expression in tumors, together with its critical role in tumor angiogenesis, integrin a v b 3 is an attractive target for tumor angiogenesis therapy.
A tripeptide arginine-glycine-aspartic acid (RGD) sequence is present in extracellular proteins such as vitronectin, fibrinogen, thrombospondin, and osteopontin. 12 The RGD motif has been found to have a high affinity for integrin a v b 3 . 7, 12, 13 Furthermore, cyclic RGD derivatives, which are based on the RGD tripeptide sequence, have a 100-fold better inhibition ability in relation to cell adhesion to vitronectin compared to the linear variant. 14, 15 Thus, cyclic RGD can be used as a potential ligand to develop targeted probes for integrin a v b 3 .
Researchers have previously labeled cyclic-RGD peptides with various radionuclides or conjugated cyclic-RGD peptides with near-infrared (NIR) fluorescence dyes; these have been used in various tumor xenograft models to evaluate tumor integrin a v b 3 expression by positron emission tomography (PET), single-photon emission computed tomography (SPECT), and NIR fluorescence camera. [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] However, the spatial resolutions of PET or SPECT are often not satisfactory, and radionuclides are often expensive and labor intensive to create. NIR imaging has an inevitable tissue penetration problem, and this restricts its clinical usefulness. Magnetic resonance imaging (MRI) is able to create cross-sectional images that have better spatial resolution, and this approach has no signal attenuation problem. 26 Researchers have previously conjugated RGD derivatives with various T 1 or T 2 contrast agents and used MRI to evaluate integrin a v b 3 expression using a number of animal models. [27] [28] [29] [30] [31] [32] [33] In these studies, the authors showed the presence of a higher contrast enhancement ratio at the tumor angiogenesis sites at specific time points after contrast injection. However, it is sometimes hard to obtain hemodynamic information from exactly the same area once the position of the mouse is changed. As a result, obtaining unbiased enhancement data from a specific portion of the tumor is difficult.
We previously reported the advantage of using dynamic contrast-enhanced (DCE) MRI to detect folate receptor (FR)-positive tumors in a mouse xenograft tumor model using a gadolinium (Gd)-loaded polyethylene glycol (PEG)-dendrimer-folate conjugate. 34 We demonstrated that a 30-minute contrast washout percentage (CWP) was a useful parameter when differentiating FR-positive tumors from FR-negative tumors. In this study, we conjugated cyclic RGD with the Gd-loaded PEG-dendrimer as an integrin a v b 3 targeting magnetic resonance (MR) contrast agent. Using DCE MRI, a Gd-loaded PEGdendrimer-cRGD conjugate was used in a mouse xenograft tumor model to evaluate tumor angiogenesis; it was also used to detect suitability for early antiangiogenic treatment whereby the patient will respond to injection of antiintegrin a v b 3 MAb 10 and anti-vascular endothelial cell growth factor (VEGF) MAb (bevacizumab). 35 
Materials and Methods

Contrast Medium
A third-generation (G3) dendrimer with 16 hydroxyl groups was prepared as described previously. 34 Next, the hydroxyl groups present at the surface of the dendrimers were used for conjugation with diethylenetriaminepentaacetic acid (DTPA). Later, the DTPA terminals were conjugated with c(RGDfK) (Peptides International Inc., Louisville, KY), as well as complexed with Gd ions (Figure 1 ).
Preparation of the PEG-G3-(DTPA) m DTPA (0.28 g, 40 equivalent [eq]), hexafluorophosphate (HBTU; 0.27 g, 40 eq), and hydroxybenzotriazole (HOBt; 0.19 g, 80 eq) were dissolved in 20 mL dimethyl sulfoxide (DMSO) under nitrogen atmosphere. The solution was stirred at room temperature for 24 hours. PEG-G3-OH 16 (0.1 g, 1 eq, 0.0178 mmol) and 1,5-diazabicyclo[4.3.0]non-5-ene (DBN) (0.07 mL, 16 eq) were dissolved in 3 mL of DMSO and stirred for 10 minutes. The DTPA solution was added dropwise into the solution of PEG-G3-OH 16 and stirred at room temperature for 2 days. The solution was then dialyzed against deionized water. Free DTPA units were removed by ultrafiltration using a molecular weight cutoff 1000 membrane.
The number of DTPA groups was determined by the chelatometric titration method. A known weight of the dendrimer was dissolved in deionized water, and ammonium buffer (pH 10) was added followed by a drop Eriochrome Black-T indicator (Thermo Fisher Scientific, Waltham, MA). This mixture was titrated against 0.1 M calcium chloride solution until the blue color turned to a reddish orange color.
Preparation of the PEG-G3-(DTPA) m-n -(cRGD-DTPA) n PEG-G3-(DTPA) m (130 mg, 0.01625 mmol), HBTU (154 mg, 25 eq), and HOBt (110 mg, 50 eq) were dissolved in 20 mL DMSO and stirred for 1 hour at room temperature. Cyclic (RGDfK) (25 mg, 2.5 eq) and N,N-diisopropylethylamine (DIPEA) (21 mg, 10 eq) were dissolved in 30 mL DMSO. The c(RGDfK) solution was added dropwise into the solution of PEG-G3-(DTPA) m and stirred at room temperature overnight under a nitrogen atmosphere. Figure 1 . Synthetic scheme used to make the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 dendrimer.
The solution was dialyzed against water to remove excess residues and filtered by spin column (Centricon, Millipore Corp., Billerica, MA) to remove low-molecularweight molecules. In addition, c(RADfK) (Peptides International) was used to synthesize PEG-G3-(DTPA) m-n -(cRAD-DTPA) n as the control contrast agent, and the same protocol was used.
Preparation of the PEG-G3-(Gd-DTPA) m-n -(cRGD-DTPA) n PEG-G3-(DTPA) m-n -(cRGD-DTPA) n (47 mg, 0.0053 mmol) was dissolved in 5 mL deionized water. GdCl3 (0.097 M, 0.273 mL) was added to the solution, and the pH was adjusted to 6.0 to 6.5 by 0.1 N NaOH and then stirred for 3 hours. The solution was filtered by spin column to remove free Gd ions and low-molecular-weight molecules and then lyophilized.
The absence of free Gd ions was confirmed using xylenol orange as the indicator at a pH of 5.8 (acetate buffer). The absence of uncomplexed DTPA units was confirmed by adopting the titration method used to determine the number of DTPA units present in the dendrimer. The number of Gd ions doped was determined experimentally using inductively coupled plasma-atomic emission spectroscopy (ICP-AES; S-35, Kontron, Germany). The complexes were filtered using a 0.45 mm filter and lyophilized. In addition, some cRGD-conjugated dendrimers were labeled with fluorescein isothiocyanate (FITC) for the cell binding experiments.
T 1 Relaxation Measurements
The Gd-loaded dendrimers (0.2-1 mmol) were evaluated for their capacity to alter the relaxation rate of water using a nuclear magnetic resonance (NMR) spectrometer (20 MHz, 0.47 T; MQ-20, Brucker, Germany) at 37uC with a standard pulse program of inversion recovery (range of repetition time: 0-300 ms). 36, 37 Real-time polymerase chain reaction (RT-PCR) and immunohistochemistry (IHC) were performed to assess the integrin a v b 3 expression. Cellular attachment experiments using FITC-labeled cRGD-conjugated dendrimer were carried out on U87 MG, KB, and small interfering ribonucleic acid (siRNA)-treated U87 MG cells.
Cell Experiments
Integrin a v RT-PCR
Total ribonucleic acid (RNA) was extracted from U87 MG and KB cells by a Qiagen RNeasy kit (Qiagen, Hilden, Germany), and 1 mg of extracted total RNA was subjected to a reverse transcription reaction using a high-capacity complementary deoxyribonucleic acid (cDNA) reverse transcription kit (Applied Biosystems, Foster City, CA). The cDNA from 20 ng of the total RNA was used as a template. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and integrin a v messenger RNA were quantified by a sequence detection system instrument (RPISM 7000, Applied Biosystems) using the TagMan Gene Expression Assay (Applied Biosystems). The integrin a v primers and probe were purchased from Applied Biosystems (Assay ID: Hs00233808_m1).
Immunohistochemistry
After fixation of the U87 MG cells using 100% ethanol, IHC was performed using a mouse antihuman integrin a v b 3 MAb (LM609, 1:50 dilution; Millipore Corp.), and this was developed with biotinylated goat antimouse secondary antibody (NEF823, 1:250 dilution; PerkinElmer, Waltham, MA). The staining procedure was performed with a modified avidin-biotin-peroxidase complex technique (PK-6100, Vector Laboratories, Burlingame, CA). The slides were visualized with the chromogen diaminobenzidine (DAB) and counterstained with hematoxylin (Vector Laboratories). Control sections were processed identically but incubated with nonspecific isotype immunoglobulin (Vector Laboratories) rather than LM609. These slides were also visualized with the chromogen DAB and counterstained with hematoxylin (Vector Laboratories).
For cryosectioning of the KB cell xenograft tumors, the tumors were dissected and cut in half, covered with TissueTek (Sakura, Torrance, CA), and then frozen in liquid nitrogen vapor. Tumor sections were cut (5 mm in thickness) with a Microm HM525 microtome (BioOptica, Milano, Italy) and were methanol/acetone fixed. The sections were next blocked using an mouse on mouse immunodetection kit (Vector Laboratories) and incubated with monoclonal mouse anti-human integrin a v b 3 antibody (LM609, 1:50 dilution, Millipore Corp.) for 2 hours. This was followed by development using biotinylated goat antimouse secondary antibody (Nb720-55595, 1:250 dilution, Novus, Littleton, CO) for 30 minutes, and then a modified avidin-biotin-peroxidase complex technique was performed as described above. Control sections were processed identically but incubated with nonspecific isotype immunoglobulin (Vector Laboratories) rather than LM609. All slides were visualized with the chromogen DAB and counterstained with hematoxylin (Vector Laboratories).
Cellular Attachment Experiments
The U87 MG and KB cells (5 3 10 4 cells) were cultured on a covered glass overnight. FITC-labeled cRGD-conjugated dendrimer (2 mM) was added to the culture medium for 2 hours, and then the cells were washed and fixed with 100% ethanol. 49,6-Diamidino-2-phenylindole (DAPI) (D8417, Sigma-Aldrich, St. Louis, MO) was used for nuclear staining. The slices were analyzed using a fluorescence microscope (Axioplan, Zeiss, Germany). Blue and green channels were used for DAPI and FITC fluorescence detection. Axiovision software (Zeiss) was used for image acquisition.
In addition, free cRGD competition and integrin b 3 siRNA knockdown experiments were performed. Two hundred-fold free cRGD (400 mM) was added to the culture medium as a competitor for integrin a v b 3 before adding the FITC-labeled dendrimer (2 mM). In another setting, the U87 MG cells were first treated with integrin a v -specific siRNA 48 hours prior to the cellular uptake study to suppress integrin a v expression. Integrin a vspecific siRNA is commercially available and was purchased from Ambion (Austin, TX) (AM_16708). Untreated U87 MG cells were used for the positive control. RT-PCR was used to validate the extent of the integrin a v knockdown. Scrambled integrin a v siRNA-(Ambion) treated U87 MG cells were used as the negative control. The integrin a v siRNA-treated U87 MG cells, the scrambled integrin a v siRNA-treated U87 MG cells, and the normal U87 MG cells were used for the FITC-labeled dendrimer cell binding studies.
Animal Preparation and Tumor Model
All animal studies were approved by the Institutional Animal Care Committee at our institution. Isoflurane inhalation was used for mice anesthesia. We delivered 1% for maintenance and 5% for induction with oxygen using a precision vaporizer (VIP3000, Midmark, Versailles, OH). Carbon dioxide inhalation was used for euthanasia. Eightweek-old nude male mice (National Laboratory Animal Center, Taipei, Taiwan), weighing 18 to 24 g (average weight 21.2 g), were handled in accordance with government guidelines.
To evaluate tumor-related integrin a v b 3 expression during tumor angiogenesis, integrin a v b 3 -negative KB cells were used to develop a xenograft tumor model. To induce solid tumors, 1 3 10 6 KB cells were injected subcutaneously into the right flank fat pads of 37 mice. Within 30 to 40 days after implantations, each mouse developed right flank tumors of 12 6 4 mm in size.
Experimental Groups
The KB tumor-bearing mice were divided into five groups: the PEG-G3-(Gd-DTPA) m-n -(cRGD-DTPA) n injection group (n 5 12), the PEG-G3-(Gd-DTPA) m-n -(cRAD-DTPA) n injection group (n 5 12), the anti-integrin a v b 3 MAb (LM609, Millipore Corp.) treatment group (n 5 3), the anti-VEGF MAb (bevacizumab, Roche, South San Francisco, CA) treatment group (n 5 4), and the nontreatment group (n 5 6).
In the PEG-G3-(Gd-DTPA) m-n -(cRGD-DTPA) n and PEG-G3-(Gd-DTPA) m-n -(cRAD-DTPA) n injection groups, efforts were made to inject both contrast agents into the same mouse to avoid intersubject biases. However, owing to anesthetic death, animal motion during examination, or venous injection failure, eventually only six mice received both cRGD-conjugated and cRAD-conjugated contrast medium injections for the DCE MRI study.
In the LM609 treatment group, pretreatment DCE MRI was performed 1 day before treatment, and then the mice received an intravenous LM609 injection via the retrobulbar venous plexus (25 mg/mouse) the next day. Finally, they received posttreatment DCE MRI 2 hours after LM609 injection.
In the bevacizumab treatment group, after performing the pretreatment DCE MRI study, the mice received an intraperitoneal injection of bevacizumab on the same day (5 mg/kg, intraperitoneal injection). The mice received posttreatment DCE MRI studies 3 and 6 days after bevacizumab treatment. A second dose of bevacizumab (5 mg/kg) was given intraperitoneally on the third day after the posttreatment DCE MRI. One mouse was sacrificed 7 days after the initiation of treatment, and the tumor was excised for anti-integrin a v b 3 IHC. The other three mice were kept, and the tumor volume was measured periodically. The tumor volume was calculated as follows: m/6 3 length 3 width 3 height. 38 Six mice did not receive antiangiogenic treatment (intraperitoneal administration of saline on the same day as the treatment groups). The tumor volumes of these mice were also measured periodically to obtain the normal growth curve of the KB cell xenograft tumors.
DCE Magnetic Resonance Imaging
MRI of the mice was performed using a 1.5 T superconducting system with a C4 surface coil. Axial DCE MRIs were then obtained with a section thickness of 2 mm and a 12 cm field of view through the centers of the bilateral flank tumors. T 1 -weighted gradient echo sequences, with TR/echo time (TE) 5 188/3.4, number of excitation 5 1, flip angle of 80u, and a 179 3 256 acquisition matrix, were used. Forty dynamic images were obtained within 30 minutes from each of the mice. A bolus of PEG-G3-(Gd-DTPA) m-n -(cRGD-DTPA) n or PEG-G3-(Gd-DTPA) m-n -(cRAD-DTPA) n dendrimer (0.1 mmol per kilogram of body weight) was administered manually through a 31-gauge needle, which was placed in the retrobulbar venous sinus of the mice before the MRI study and connected to a 300 mL syringe through a polyethylene tube.
Data Analysis
Signal intensity (SI) values were measured in the operatordefined regions of interest (ROI). The ROI were placed by one investigator (W.-T.C.) with the aid of a cursor and graphic display device and encircled the entire tumor using an axial image through the bilateral tumor centers. SI was then measured for the KB tumors. The SI values derived from the ROI were plotted against time (0-30 minutes) as a time-intensity curve (TIC) by a software system (Extended MR WorkSpace, Philips, Best, Netherlands). The baseline value for signal intensity (SI base ) on a TIC was defined as the mean signal intensity from the first two images. The peak signal intensity (SI peak ) was defined as the peak enhancement value during the first pass of contrast medium. SI 30min was defined as the signal intensity measured 30 minutes after contrast injection. The contrast enhancement rise time (T rise ) was defined as the time between SI base and SI peak . The contrast washout time (T washout ) was defined as the time between SI peak and SI max .
The 
Patterns of TICs
The TICs were classified into three types. Type A represents an initial rapidly rising slope followed by a second slowly rising phase (persistent enhancement curve). Type B represents a rapidly rising slope (wash-in) during the early phase, followed by a plateau after the peak enhancement. Type C represents a rapidly rising slope (wash-in), the same as the upright portion of the type B curve, followed by a washout phenomenon during the latter phase. Any change from 25 to 5% was considered to be a type B curve (plateau). More than 5% change was considered a type A curve. Any change to less than 25% was considered to be a type C curve. 39 
Statistical Analysis
The results are presented as mean 6 standard deviation. Differences in results acquired from the DCE MRI were compared using the Student t-test. The Fisher exact test was used to analyze the distribution of TIC patterns across the different groups. A value of p , .05 was considered to show significant difference. Statistical analysis was done with Stata 7 for Windows (Stata Corporation, College Station, TX).
Results
Contrast Medium
The synthesis of PEG-G3 dendrimer proceeded as previously described. 34 The formation of the G3 dendrimer was confirmed by 1 H NMR spectrometry and matrixassisted laser desorption/ionization-time of flight (MALDI-TOF).
Synthesis of the PEG-G3-(DTPA) 8 The number of DTPA units attached to the G3 dendrimer was calculated from the volume of calcium chloride consumed. The average number of DTPA units present in each molecule of the cRGD-conjugated G 3 dendrimer was calculated to be eight.
Synthesis of the PEG-G3-(DTPA) 6 -(cRGD-DTPA) 2 The number of cRGD units attached was calculated from the MALDI-TOF experiments by comparing the molecular weight of the reactant and the product. The average number of cRGD units present in each molecule of the PEG-G3-(DTPA) 8 dendrimer was calculated to be two.
Integrin
Synthesis of the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 Inversion recovery spectroscopy demonstrated that the DTPA ligands were complexed with Gd, which was identified by the disappearance of the C-O stretching vibration around 1,200 cm -1 and the shift of the carbonyl stretch from 1,638 to 1,598 cm -1 . The number of Gd ions doped on each dendrimer was 5.5, as calculated by ICP-AES. The molecular weight of the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 dendrimer was about 10,235 kDa (see Figure 1 ).
T 1 Relaxation Measurements
The Gd-loaded cRGD-conjugated dendrimers were evaluated for their capacity to alter the relaxation rate of water using an NMR spectrometer (20 MHz, 0.47 T) with a standard pulse program of inversion recovery. The calculated r1 of the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 Figure 2A ) but not on the KB cells or on the nonspecific immunoglobulin control slide. After 7 days of bevacizumab treatment, the cryosections of the posttreatment KB cell xenograft tumors showed much less brown staining along the tumor vasculature after exactly the same treatment, when the post-bevacizumab treatment KB tumors ( Figure 2B ) were compared to the nontreatment sections.
Cellular Attachment Experiments
After 2 hours of incubation of FITC-labeled cRGDconjugated dendrimer (2 mM) with U87 MG cells, strong green fluorescence spots were detectable at the cell surface of U87 MG cells by fluorescence microscopy (Axioplan, Zeiss) ( Figure 3, A and B ), but these were not present in the FITC-labeled cRAD-conjugated dendrimer group (data not shown). In the competition setting, 200-fold free cRGD (400 mM) was added to the culture medium before adding the FITC-labeled dendrimer; no green fluorescence was then detected on the cRGD presaturated U87 MG cells ( Figure 3C ). In another setting, when the integrin a v siRNA-treated U87 MG cells were incubated with the FITC-labeled dendrimer (2 mM) for 2 hours, very little green fluorescence was detectable by fluorescence microscopy ( Figure 3D ), but green fluorescence could be seen in the control GAPDH siRNA-treated U87 MG cells. The KB cells showed no green fluorescence in each situation (data not shown).
MRI and Data Analysis
Comparison of DCE MRI Parameters between the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 and PEG-G3-(Gd-DTPA) 6 -(cRAD-DTPA) 2 
Injection Groups
The enhancement percentage and enhancement slope of the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 injection group (n 5 12) and the control groups (n 5 12) showed no significant difference (enhancement percentage: 10.8 6 4.4% vs 12.1 6 4.9%; enhancement slope: 2.5 6 1.1%/min vs 2.8 6 1.3%/min). The 30-minute CWP and 30-minute contrast washout slope of the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 injection and control groups showed a significant difference (30-minute CWP: 25.5 6 6.4% vs 7.3 6 8%; contrast washout slope: 20.2 6 0.3%/min vs 0.3 6 0.3%/min, p , .001) ( Figure 4A ). The distribution of TIC types in the two groups is shown in Table 1 . All of the type A curves were found in the cRGD-dendrimer injection group ( Figure 4B ). Eight (75%) of 12 type B curves were found in the cRGDdendrimer injection group. All of the eight type C curves were found in the cRAD-dendrimer injection group ( Figure 4C ). There was a statistically significant difference in the distribution of the TIC patterns between the two groups (p , .001) by Fisher exact test.
Assessment of the Treatment Response of LM609
In the pre-LM609 treatment DCE MRI studies, the average 30-minute CWP of tumors was 26.8 6 4% (n 5 3), whereas the average 30-minute CWP of tumors was 3.1 6 2.2% at 2 hours after LM609 MAb injection ( Figure 5 ) (p , .05). The LM609-treated KB tumors showed a slower tumor growth rate than the nontreated KB tumors after LM609 treatment (see Figure 5C ).
Assessment of the Treatment Response to Bevacizumab
In the prebevacizumab treatment DCE MRI studies, the average 30-minute CWP of tumors was 28 6 4.2% (n 5 4). The average 30-minute CWP of the tumors 3 days after bevacizumab treatment was significantly increased to be 1.5 6 2.2% and reached 7.9 6 6.6% at 6 days after initiation of the bevacizumab treatment (n 5 4). A significant progressive increase in the average 30-minute CWP was noted for all mice (Figure 6 ) during the first 6 days after treatment. All of the bevacizumab-treated tumors had switched their enhancement pattern to type C at 6 days after the initiation of bevacizumab treatment. A tumor volume decrease was observed in all three bevacizumab-treated mice (except the one sacrificed for the IHC study) during the 40-day observation period, whereas all nontreated mice showed a progressive enlargement in tumor volume (see Figure 6B) .
Discussion
Owing to the differential upregulation of integrin a v b 3 in proliferating versus quiescent endothelial cells, integrin a v b 3 is frequently regarded as a neovascular biomarker and is also an attractive target for molecular imaging. Our results showed that a cRGD-conjugated Gd-loaded dendrimer can target integrin a v b 3 -positive U87 MG human glioblastoma cells and that this attachment phenomenon can be suppressed by adding excessive free cRGD and is also diminished in the integrin a v siRNA-treated U87 MG cells. In the DCE MRI study, the cRGD-conjugated Gdloaded dendrimer demonstrated a persistent enhancement phenomenon compared to the control cRAD-conjugated contrast agent. The specificity of this integrin a v b 3 -targeting contrast agent was confirmed by the antiintegrin a v b 3 MAb treatment study, which also indicated the potential role of this cRGD-conjugated contrast agent in the assessment of anti-integrin a v b 3 -targeted therapy. 37, 40 The 30-minute CWP revealed a hemodynamic change 2 hours after LM609 treatment and 3 days after bevacizumab treatment. Our data demonstrated that the cRGD-conjugated Gd-loaded dendrimer has a potential role in identifying tumor angiogenesis and in monitoring treatment response to antiangiogenic therapy. The RGD motif has high affinity for the integrin family of cell adhesion molecules; this is true not only for integrin a v b 3 but also for integrin a 5 b 1 .
12 Integrin a 5 b 1 is also overexpressed in tumor blood vessels in response to angiogenic factors but is not expressed in quiescent cells. [41] [42] [43] Schmieder and colleagues showed that a cRGD-conjugated nanoparticle can also target integrin a 5 b 1. 33 Hence, the cRGD conjugate is a robust ligand for detecting tumor angiogenesis because it can target various angiogenesis-related integrin family members. 33 Kim and colleagues showed that bevacizumab treatment can inhibit integrin family expression, including integrin a 5 b 1 and a v b 3 . 35 Hence, cRGD conjugates can serve as a potential beacon for evaluation of the treatment response to bevacizumab therapy. Figure 4 . A, The dot plot distribution of the 30-minute contrast washout percentage in the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 and PEG-G3-(Gd-DTPA) 6 -(cRAD-DTPA) 2 injection groups. The 30-minute contrast washout percentage was 25.5 6 6.4% in the cRGD-conjugated dendrimer injection group and 7.3 6 8% in the cRAD-conjugated dendrimer injection group, p , .001. Six mice received both cRGD-conjugated and cRAD-conjugated contrast medium (solid lines). The 30-minute contrast washout percentage in these six pairs of data still shows a significantly lesser value in the cRGD-conjugated contrast medium injection group (27.4 6 8.8% vs 10.2 6 10.8%, p , .05). B, The time-intensity curve (TIC) obtained from the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 injection group, which shows a persistent enhancement pattern (type A). C, The TIC obtained from the same mouse but using PEG-G3-(Gd-DTPA) 6 -(cRAD-DTPA) 2 , which shows a contrast washout pattern (type C).
In the pilot study, we applied the conventional enhancement method to compare the enhancement ratio of the different groups at various time points (4 hours, 8 hours, 12 hours, etc.) after contrast medium injection, as other authors did in previous integrin a v b 3 -targeting MR studies. [27] [28] [29] [30] [31] [32] [33] However, we found that it was difficult to image in exactly the same plane of the xenograft tumors once we had rearranged the mouse position. We also observed a fluctuated baseline MR signal intensity at various time points, which was caused by MR unit internal variability. This might cause measurement bias problems between series of MRI studies. In a clinical situation, it also might not be practical to follow the patient for such a long period. DCE MRI can acquire enhancement data from exactly the same portion of tumor during an examination and assess the semiquantitative pharmacokinetic characteristics of the contrast agent, such as the 30-minute CWP. We have also demonstrated the benefit of 30-minute CWP in terms of its ability to differentiate FR-positive tumors in our previous study using FR-targeting contrast medium.
34 Table 1 . Distribution of Time-Intensity Curve Types in the PEG-G3-(Gd-DTPA) 6 -(cRGD-DTPA) 2 and PEG-G3-(Gd-DTPA) 6 -(cRAD-DTPA) 2 In this study, we demonstrated that a cRGD-conjugated macromolecular MR contrast medium was more ''sticky'' to active endothelial cells during tumor angiogenesis and that this phenomenon was revealed by a negative value for the 30-minute CWP. This gave a useful baseline reference in terms of monitoring the tumor hemodynamic response to antiangiogenic therapy.
DCE MRI is a valuable imaging tool for tumor angiogenesis. [44] [45] [46] A two-compartment bidirectional exchange kinetic model has often been used in DCE MRI studies. However, we think that the two-compartment model is not suitable for receptor-targeted MRI. The ligand-conjugated contrast medium has a high affinity for target molecules and should remain longer within the Figure 6 . Progression of the time-intensity curve (TIC) pattern from type A to type C in a KB tumor-bearing mouse after bevacizumab treatment. A, The TICs were obtained from the same mouse before and on days 3, 6, 20, and 40 after bevacizumab treatment using cRGD-conjugated Gdloaded dendrimers. B, The tumor growth curves of the bevacizumab-treated mouse and two other untreated mice. Two mice received intraperitoneal normal saline injection when the other mouse received bevacizumab treatment (5 mg/kg) (day 0, arrowhead). The days on which posttreatment dynamic contrast-enhanced magnetic resonance imaging took place are indicated by arrows. Another dose of bevacizumab was given 3 days after day 0, while at the same time, the other two mice received normal saline injection. C, A progressive increase in the 30-minute contrast washout percentage can be seen over the first 6 days after the initiation of bevacizumab treatment (Tx) in all four mice. target tissues. As a result, it is difficult to create and use a suitable model or formula to assess the hemodynamics of the receptor-targeting contrast agents.
All of the bevacizumab-treated KB tumors showed a progressive decrease in tumor size over the 40-day observation period even though only two doses of bevacizumab were given on days 0 and 3. Our results showed that the KB cell xenograft tumor model is a bevacizumab responder. However, some targeted cancer therapies are particularly effective in a specific subpopulation of patients. Clinicians therefore need to be able to predict the therapeutic benefit of a particular treatment at the patient level. Piessevaux and colleagues reported that tumor shrinkage at week 6 is a reliable and accessible tool for predicting the efficacy of cetuximab when treating chemorefractory metastatic colorectal cancer. 47 In this study, integrin a v b 3 -targeted DCE MRI has been demonstrated as having the ability to identify in advance bevacizumab responders even before there is a decrease in tumor size. This finding could have a significant impact on the assessment of treatment responses to novel targeted cancer therapies in the future.
To obtain an unbiased comparison of the hemodynamic data between the different groups, we measured the entire cross-sectional area of each tumor. However, based on our observations, the vascularity of the peripheral zone of the xenograft tumors was higher than the central zone and there was a peripheral enhancement pattern in KB xenograft tumors. When we applied a smaller ROI to the peripheral enhanced regions of the KB tumors, we found a persistent contrast fill-in pattern that was greater in the cRGD-dendrimer injection group (data not shown). Although a peripheral enhancement pattern also was observed with the control cRAD-dendrimer group, their TIC also showed a contrast washout phenomenon.
During the synthesis of the conjugation of DTPA with the PEG-G3 dendrimer, we found that it was difficult to saturate all of the 16 hydroxyl groups on the dendrimer. The average number of DTPA units per dendrimer was six to eight over several attempts. We presumed that this might be due to steric hindrance. However, our dendrimer carried an average of six Gd-DTPA units per dendrimer to allow MR signal magnification. The r1 of our contrast agent was 25.6 (mM.S) -1 per dendrimer, which is 8.8-fold higher than a single molecule of Gd-DTPA [2.9(mM.S) -1 ]. Our results demonstrated the beneficial effect of increased T 1 relaxivity per molecule when using dendrimeric Gd chelates. 48 To avoid intersubject variation, we intended to use both cRGD-conjugated and cRAD-conjugated Gd-loaded contrast agents on the same mouse when we began our study. However, owing to anesthesia problems and venous injection failure, eventually only six mice received both cRGD-conjugated and cRAD-conjugated contrast medium during the DCE MRI study. The difference in 30-minute CWP in these six pairs of data still showed a significant difference between the cRGD-and cRADconjugated contrast medium injection groups. Such pairwise comparison provided stronger and nonbiased evidence that the cRGD-conjugated Gd-loaded dendrimer stayed significantly longer at the sites of tumor-related angiogenesis.
We demonstrated a decrease in integrin a v b 3 expression in the KB cell xenograft tumor model by IHC and also demonstrated that the 30-minute CWP gradually increased over the 6 days after bevacizumab treatment. Nonetheless, it is possible that this phenomenon might also be contributed to by a decrease in vessel permeability after bevacizumab treatment, which is well documented in the literature. 49 However, the change in 30-minute CPW remains a potential parameter that is able to define the baseline hemodynamic status before antiangiogenic therapy while allowing semiquantitative assessment of the hemodynamic changes in response to antiangiogenic therapy.
We observed one case in the cRGD conjugate injection group where a mild contrast washout phenomenon was present during the first 30 minutes (see Figure 4a , left row). We presumed that it might be caused by tumor-related arteriovenous shunting. 50 In such case, the blood flow velocity of tumor microvasculature will be exceptionally fast, and contrast washout phenomenon could be accelerated.
One of the drawbacks of this study is that we used a 1.5 T MR magnet for mouse tumor imaging. The imaging resolution (0.47 mm/pixel), signal to noise ratio, and contrast to noise ratio were not as good as with high magnetic MR units designed for small animals. However, the average tumor size was 1.1 cm in our study (range 0.8-1.5 cm). This range in tumor size is clearly revealed by a 1.5 T MR magnet using a small wrist surface coil. Another drawback of this project is that we did not perform quantitative correlation analysis between the xenograft tumor integrin a v b 3 expression level with the 30-minute CWP, but we have demonstrated a qualitative negative correlation between the tumor integrin a v b 3 expression level and the 30-minute CWP (see Figure 2) . Another limitation of this study is that we did not show how the 30-minute CWP changes in nonresponders after antiangiogenic therapy. This was because it is hard to develop an appropriate nonresponse animal model.
In this study, we have demonstrated not only that the use of cRGD-conjugated Gd-loaded dendrimer, based on a negative 30-minute CWP acquired by DCE MRI, is able to detect overexpression of integrin a v b 3 but also that this approach provides a valuable parameter that can be used to assess treatment response to antiangiogenic treatment; the latter assessment can be done before there is a decrease in tumor size, which is the previous approach to such assessment. In conclusion, DCE MRI using a cRGDconjugated Gd-loaded dendrimer is a promising semiquantitative methodology for molecular imaging of integrin a v b 3 expression in vivo and has a potential and promising role in the early assessment of antiangiogenic therapy.
